Asia Pacific Organ-on-a-Chip Market

Asia Pacific Organ-on-a-Chip market was valued USD 6.85 Million in 2023 and projected to reach USD 80.15 Million by 2030, growing at a CAGR of 41.1% during the forecast period of 2023-2030.

The Asia-Pacific market for organ-on-chip (OOC) is experiencing significant growth due to various factors, presenting numerous opportunities. This expansion is driven by increased research efforts, partnerships between organizations, and the growing use of OOC technology by pharmaceutical companies. Leading institutions in countries like Singapore, South Korea, and Japan, such as the Institute of Bioengineering and Nanotechnology (IBN) and the RIKEN Institute, are at the lead of OOC advancements. They are nurturing innovation and establishing collaborations with industry counterparts. Pharmaceutical giants in the region, including Takeda Pharmaceutical and Daiichi Sankyo, are utilizing OOC platforms to enhance preclinical assessments. This enables them to make more accurate predictions about drug responses and develop safer and more personalized medications that cater to regional needs. OOC technology is being applied to analyze specific diseases prevalent in the region, such as liver disorders. This provides valuable insights into local health challenges and facilitates the development of targeted treatments. Collaborations between startups, research institutions, and established companies, along with efforts to raise awareness and educate professionals about OOC technology, are driving innovation and accelerating its adoption. With continued investment, technological advancements, and collaborative initiatives, the Asia-Pacific OOC market is poised for significant progress. This will have transformative effects on healthcare research and drug discovery in the region.

Growth of pharmaceutical and biotechnology industries

The Asia Pacific organ-on-a-chip market is being driven by the rapid expansion of the pharmaceutical and biotechnology sectors. Factors such as increased healthcare spending, a rise in chronic illness prevalence, and a growing demand for innovative healthcare solutions are contributing to the significant growth of these industries in the region. Pharmaceutical and biotechnology companies are investing heavily in research and development efforts, including the incorporation of organ-on-a-chip technology into drug discovery, preclinical testing, and personalized medicine projects. This favorable growth environment is promoting the adoption and advancement of organ-on-a-chip platforms, leading to market expansion and the establishment of collaborative partnerships between industry players and research organizations.

Market Dynamics

Drivers:

• Growth of pharmaceutical and biotechnology industries

• Aging Population and Increasing Disease Burden
• Growing movement to reduce reliance on animal testing for drug development

Opportunities:

• Making organ-on-a-chip platforms more affordable and user-friendly

• Integration of artificial intelligence (AI) into OOC systems
• Technological advancements in OOC platforms

Making organ-on-a-chip platforms more affordable and user-friendly

There is an opportunity in the Asia Pacific organ-on-a-chip market to improve the affordability and user-friendliness of these platforms. By optimizing manufacturing processes and sourcing materials efficiently, production costs can be lowered, making organ-on-a-chip technology more accessible to research institutions and smaller biotech firms in the area. Additionally, enhancing the simplicity of operating and maintaining organ-on-a-chip systems through user-friendly interfaces and automation features can enhance usability and effectiveness, attracting a wider range of users and encouraging adoption. By addressing concerns about affordability and usability, companies can reach a larger market segment, promoting the adoption of organ-on-a-chip platforms and encouraging innovation in biomedical research and drug development across the Asia Pacific region.

The liver-on-chip segment is anticipated to hold the largest market share during the forecast period

In the Asia-pacific Organ-on-a-Chip market, the Organ Type segment comprises various categories such as Liver-on-a-Chip, Heart-on-a-Chip, Lung-on-a-Chip, Kidney-on-a-Chip, Intestine-on-a-Chip, and Other Organs. The liver-on-chip segment is poised to lead the Asia Pacific organ-on-a-chip market due to its crucial role in drug metabolism and toxicity testing. Liver-on-chip platforms offer relevant models for preclinical drug assessment, which is increasingly important in drug safety and personalized medicine. Additionally, the continuous improvements in liver-on-chip technology greatly improve the accuracy of drug response forecasts, driving their widespread adoption and expected market dominance in the foreseeable future.

Major vendors in the Asia-pacific Organ-on-a-Chip market include Anhui Luohua Biotechnology Co. Ltd., Beijing Daxiang Biotech Co., Ltd, (CN Bio Innovations Limited.) MineBio Life Sciences Limited, Goma Biotech Co., Ltd., MEPSGEN Co., Ltd., Nikon Instruments Inc., Qureator, Ushio Inc., Venus Remedies Limited and Others.

Segmentations Analysis of Asia Pacific Organ-on-a-Chip Market: –

Major Segmentations Are Distributed as follows:

• By Organ Type
  • Liver-on-a-Chip
  • Heart-on-a-Chip
  • Lung-on-a-Chip
  • Kidney-on-a-Chip
  • Intestine-on-a-Chip
  • Other Organs
• By Application Focus
  • Drug Discovery and Development
  • Disease Modeling
  • Toxicology Studies
  • Precision Medicine
  • Regenerative Medicine
  • Others
• By   Technology Platforms
  • 3D Bioprinting
  • Hydrogel-Based OOC
  • Scaffold-Based OOC
• By   Technology Platforms
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutions
  • Contract Research Organizations (CROs)

Recent Developments

In Jan 2024, CN Bio and Altis Biosystems, Inc. revealed a strategic collaboration. In this venture, Altis’ human RepliGut Planar-Jejunum model will merge with CN Bio’s PhysioMimix Liver-on-a-chip technology. This integration aims to establish a primary human microphysiological system (MPS) capable of intra-organ communication, specifically designed to simulate the oral drug administration pathway.

Asia Pacific Organ-on-a-Chip Market Report Gives Answers to Following Key Questions:

• What will be the Asia Pacific Organ-on-a-Chip Market’s Trends & growth rate? What analysis has been done of the prices, sales, and volume of the top producers of Asia Pacific Organ-on-a-Chip Market?
• What are the main forces behind the worldwide Asia Pacific Organ-on-a-Chip Market? Which companies dominate the Asia Pacific Organ-on-a-Chip Market?
• Which companies dominate the Asia Pacific Organ-on-a-Chip Market? Which business possibilities, dangers, and tactics did they embrace in the market?
• What are the Asia-pacific Organ-on-a-Chip industry’s suppliers’ opportunities and dangers in Asia Pacific Organ-on-a-Chip Market?
• What is the Organ-on-a-Chip industry’s regional sales, income, and pricing analysis? In the Asia Pacific Organ-on-a-Chip Market, who are the distributors, traders, and resellers?
• What are the main geographic areas for various trades that are anticipated to have astounding expansion over the Asia Pacific Organ-on-a-Chip Market?
• What are the main geographical areas for various industries that are anticipated to observe an astounding expansion in Asia Pacific Organ-on-a-Chip Market?
• What are the dominant revenue-generating regions for Asia Pacific Organ-on-a-Chip Market, as well as regional growth trends?
• By the end of the forecast period, what will the market size and growth rate be?
• What are the main Asia Pacific Organ-on-a-Chip Market trends that are influencing the market’s expansion?
• Which key product categories dominate the Asia Pacific Organ-on-a-Chip Market? What are the Asia Pacific Organ-on-a-Chip Market’s main applications?

In the coming years, which Asia Pacific Organ-on-a-Chip Market technology will dominate the market?